Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.25 USD | -1.23% | -6.09% | +47.36% |
14/05 | Acrivon Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
30/04 | North American Morning Briefing : More Earnings -2- | DJ |
Business Summary
Number of employees: 60
Managers
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 62 | 01/18/01 | |
Kristina Masson
FOU | Founder | 44 | 01/18/01 |
Director of Finance/CFO | 53 | 01/22/01 | |
Monica Phadnis
CTO | Chief Tech/Sci/R&D Officer | - | - |
Bruce Close
CMP | Compliance Officer | - | - |
Karl Hsu
CTO | Chief Tech/Sci/R&D Officer | - | 03/01 |
Chief Tech/Sci/R&D Officer | - | 03/01 | |
Eric Devroe
COO | Chief Operating Officer | 46 | 01/22/01 |
Adam Levy
IRC | Investor Relations Contact | - | 20/23/20 |
Comptroller/Controller/Auditor | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 55 | 08/02 | |
Sharon Shacham
BRD | Director/Board Member | 53 | 01/20/01 |
Chief Executive Officer | 62 | 01/18/01 | |
Michael Tomsicek
BRD | Director/Board Member | 58 | 01/22/01 |
Charles Baum
BRD | Director/Board Member | 65 | 22/23/22 |
Derek DiRocco
BRD | Director/Board Member | 43 | 01/21/01 |
Kristina Masson
FOU | Founder | 44 | 01/18/01 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 30,876,932 | 18,439,513 ( 59.72 %) | 0 | 59.72 % |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+47.36% | 22Cr | |
+51.85% | 5.79TCr | |
+41.42% | 4.03TCr | |
-5.25% | 3.99TCr | |
-5.16% | 2.85TCr | |
+12.79% | 2.64TCr | |
-20.18% | 1.93TCr | |
+30.88% | 1.24TCr | |
+0.61% | 1.22TCr | |
+25.06% | 1.22TCr |
- Stock Market
- Equities
- ACRV Stock
- Company Acrivon Therapeutics, Inc.